⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16878256 | 1.00 | — | — | |
| SCHEMBL5645022 | 0.97 | — | — | |
| SCHEMBL16878640 | 0.93 | — | — | |
| SCHEMBL16877683 | 0.93 | — | — | |
| SCHEMBL16877459 | 0.90 | — | — | |
| SCHEMBL16878356 | 0.90 | — | — | |
| SCHEMBL16877990 | 0.90 | — | — | |
| SCHEMBL16878127 | 0.90 | — | — | |
| SCHEMBL16878449 | 0.90 | — | — | |
| SCHEMBL16878924 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-26 | — | — | US | disclosed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-3992176-B1 | EP2 ANTAGONIST | ONO PHARMACEUTICAL CO (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4596555-A1 | ABHD6 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-20250042870-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| WO-2024190777-A1 | TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024190780-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR KIDNEY DISEASES CONTAINING TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICAL CO., LTD | 2006-07-06 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1661879-A1 | DIPHENYL ETHER COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1522314-A1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |